<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04180943</url>
  </required_header>
  <id_info>
    <org_study_id>1422773</org_study_id>
    <nct_id>NCT04180943</nct_id>
  </id_info>
  <brief_title>Liposomal Bupivacaine Versus Bupivacaine for for Postoperative Pain Control in Shoulder Surgery</brief_title>
  <official_title>Liposomal Bupivacaine Versus Bupivacaine for Interscalene Nerve Block for Postoperative Pain Control in Shoulder Arthroplasty/Arthroscopy: a Prospective Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bassett Healthcare</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bassett Healthcare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, single blinded clinical trial whose purpose is to assess the impact of&#xD;
      liposomal bupivacaine (LB) in a single shot interscalene nerve block compared with standard&#xD;
      bupivacaine (same dose) in a single shot interscalene nerve block in terms of postoperative&#xD;
      pain control. Specifically, outpatient pain scores,use of postoperative pain medicine and&#xD;
      patient-reported functional outcomes after shoulder arthroplasty surgery will be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:&#xD;
&#xD;
      Shoulder arthroplasty is the fastest growing joint replacement surgery in the United States,&#xD;
      and optimal postoperative pain management is critical to optimize outcomes for these&#xD;
      surgeries. LB has gained popularity for its potential to provide extended postoperative pain&#xD;
      relief with possibly fewer side effects. LB (Exparel, Pacira Pharmaceuticals, Inc.,&#xD;
      Parsippany, NJ, USA) has recently gained popularity for its potential to provide extended&#xD;
      postoperative pain relief and was recently approved by the FDA for use in interscalene nerve&#xD;
      blocks. Several studies have investigated its efficacy after hip and knee arthroplasty and&#xD;
      demonstrated efficacy with decreased opioid consumption, early mobilization, lower hospital&#xD;
      costs, and shorter length of stay for patients undergoing surgeries such as bunionectomy,&#xD;
      open colectomy, umbilical hernia repair, breast augmentation, and total knee arthroplasty.&#xD;
      Limited studies have evaluated the efficacy of LB for perioperative pain control in shoulder&#xD;
      arthroplasty. Hence, the objective of this study is to determine whether the use of an&#xD;
      LB-based multimodal analgesic regimen provides better postoperative pain control and patient&#xD;
      satisfaction, greater cost effectiveness, and lower risk profile compared with standard&#xD;
      bupivacaine in interscalene nerve bloc&#xD;
&#xD;
      Study Design and Methods:&#xD;
&#xD;
      This will be a prospective, randomized, single blinded, controlled clinical trial comparing&#xD;
      patients undergoing shoulder arthroscopy and arthroplasty treated with LB versus standard&#xD;
      bupivacaine with a single bolus interscalene block. The block administrator will not be&#xD;
      blinded. The patient and the staff members conducting the follow up assessments, phone calls,&#xD;
      and data collection will be blinded to treatment assignment. Study drug administrators&#xD;
      (anesthesiologists) will not be blinded. There will be at least one unblinded study&#xD;
      coordinator who will not be involved in collecting outcome data.&#xD;
&#xD;
      Patients will be randomized in 1:1 ratio to LB or standard bupivacaine with a single bolus&#xD;
      interscalene block. Patient will receive the assigned interscalene block preoperatively per&#xD;
      usual procedure. The primary outcome, time to first post operative pain medication will be&#xD;
      recorded either from the medical record if administered in the hospital or via telephone&#xD;
      assessment if consumed outside the hospital. Study staff will contact the patient by phone&#xD;
      post op day (POD) 1, 2, and 3 to assess pain levels, pain medication consumption, sleep, and&#xD;
      adverse events. The total participation time for each patient will be approximately four days&#xD;
      (operative day and POD 1,2,3).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 13, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to first post-operative pain medication consumption in minutes from discharge from OR</measure>
    <time_frame>72 hours</time_frame>
    <description>time to first post-operative pain medication</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Worst daily post-op pain on a scale 1-10</measure>
    <time_frame>72 hours</time_frame>
    <description>patient reported outcome of pain severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Least daily post-op pain on a scale 1-10</measure>
    <time_frame>72 hours</time_frame>
    <description>patient reported outcome of pain severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average daily post-op pain on a scale 1-10</measure>
    <time_frame>72 hours</time_frame>
    <description>patient reported outcome of pain severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total opioid use in morphine equivalents in the first 72 hours post-op</measure>
    <time_frame>72 hours</time_frame>
    <description>Total post-op opioid use</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Anesthesia, Local</condition>
  <arm_group>
    <arm_group_label>liposomal bupivicaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>interscalene nerve block using liposomal bupivacaine (Exaprel) 10 ml mixed with 0.5% bupivacaine in same syringe - volume of bupivacaine per MD based on pt weight, etc but CANNOT EXCEED 13mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bupivicaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>interscalene block using standard bupivicaine (combination of ropivacaine 0.5% and lidocaine 2%) (volume per MD based on pt weight) + decadron</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>interscalene nerve block</intervention_name>
    <description>intra and post-operative analgesia</description>
    <arm_group_label>bupivicaine</arm_group_label>
    <arm_group_label>liposomal bupivicaine</arm_group_label>
    <other_name>liposomal bupivicaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients aged 18 years or older&#xD;
&#xD;
          -  undergoing shoulder arthroscopy or arthroplasty&#xD;
&#xD;
          -  must meet the criteria for standard of care of ambulatory surgery patients per&#xD;
             anesthesia guidelines issued by the American Society of Anesthesiologists&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  contraindications to regional anesthesia,&#xD;
&#xD;
          -  allergy to any component of multimodal analgesia&#xD;
&#xD;
          -  history of opioid use of &gt;50 morphine milligram equivalents (MME) daily,&#xD;
&#xD;
          -  significant peripheral neuropathy or neurologic disorder affecting the upper&#xD;
             extremity,&#xD;
&#xD;
          -  cognitive or psychiatric condition that might affect the patient?s assessment or&#xD;
             inability to provide informed consent&#xD;
&#xD;
          -  pregnancy (this is an exclusion for surgery as well)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linda Demma, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bassett Healthcare</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Victory, RN</last_name>
    <phone>607-547-6965</phone>
    <email>jennifer.victory@bassett.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Catherine Gilmore, RN</last_name>
    <phone>607-547-7926</phone>
    <email>catherine.gilmore@bassett.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bassett Healthcare Network</name>
      <address>
        <city>Cooperstown</city>
        <state>New York</state>
        <zip>13326</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Victory, RN</last_name>
      <phone>607-547-6965</phone>
      <email>jennifer.victory@bassett.org</email>
    </contact>
    <contact_backup>
      <last_name>Catherine Gilmore, RN</last_name>
      <phone>607-547-7926</phone>
      <email>catherine.gilmore@bassett.org</email>
    </contact_backup>
    <investigator>
      <last_name>Linda Demma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kristen Herbst, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 26, 2019</study_first_submitted>
  <study_first_submitted_qc>November 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2019</study_first_posted>
  <last_update_submitted>February 9, 2021</last_update_submitted>
  <last_update_submitted_qc>February 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bassett Healthcare</investigator_affiliation>
    <investigator_full_name>Linda Demma, MD, PhD</investigator_full_name>
    <investigator_title>attending physician - anesthesiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD will not be available to other researchers outside of the study investigators.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 5, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/43/NCT04180943/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

